<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01806597</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457A2312</org_study_id>
    <secondary_id>2012-005412-25</secondary_id>
    <nct_id>NCT01806597</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis</brief_title>
  <acronym>GESTURE</acronym>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Palmoplantar Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose of the study was to demonstrate the efficacy of secukinumab versus placebo on
      palmoplantar psoriasis and to assess the long term efficacy, safety and tolerability of
      secukinumab.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 19, 2013</start_date>
  <completion_date type="Actual">November 2, 2016</completion_date>
  <primary_completion_date type="Actual">November 2, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentages of Participants With Palmoplantar Investigator Global Assessmnet (ppIGA) 0 or 1 Response After 16 Weeks of Treatment</measure>
    <time_frame>Week 16</time_frame>
    <description>palmoplantar Investigator's Global Assessment (ppIGA) response after 16 weeks of treatment. To be considered a ppIGA responder at Week 16, a subject must have ppIGA of 0 or 1 at Week 16 and a reduction of at least 2 points on the ppIGA scale from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentages of Participants With Palmoplantar Investigator Global Assessment (ppIGA) 0 or 1 Response - Treatment Period I</measure>
    <time_frame>Week 1, week 2, week 4, week, 8, week 12, week 16</time_frame>
    <description>ppIGA: Palmoplantar Ivestigator's Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Based on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With ppIGA 0 or 1 Response (Observed Cases) - Treatment Period II</measure>
    <time_frame>Week 16, Week 20, Week 28, Week 32, Week 64, Week 132</time_frame>
    <description>ppIGA: Palmoplantar Ivestigator's Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Based on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentages of Subjects With ppIGA 0 or 1 Response (Observed Cases) - Entire Treatment Period</measure>
    <time_frame>Week 16, Week 24, Week 28, Week 80</time_frame>
    <description>ppIGA: Palmoplantar Ivestigator's Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Based on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline for Palmoplantar Psoriasis Area and Severity Index (ppPASI) Score -Treatment Period I</measure>
    <time_frame>Week 1, Week 2, Week 4, Week 8, Week 12, Week 16</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline for Palmoplantar Psoriasis Area and Severity Index (ppPASI) Score (Observed Cases) - Entire Treatment Set</measure>
    <time_frame>Week 16, Week 32, Week 80, Week 132</time_frame>
    <description>Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Developing Anti-secukinumab Antibodies</measure>
    <time_frame>Over time up to week 132</time_frame>
    <description>To investigate the development of immunogenicity against secukinumab</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">205</enrollment>
  <condition>Moderate to Severe Palmoplantar Psoriasis</condition>
  <arm_group>
    <arm_group_label>secukinumab 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 150 mg were dosed weekly for the first five weeks, then every four weeks up to and including Week 128. To maintain blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>secukinumab 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects assigned to secukinumab 300 mg were dosed weekly for the first five weeks and then every four weeks up to and including Week 128. In order to maintain the blinding, subjects received additional placebo injections at Weeks 17, 18 and 19. All doses of study treatment were administered by sub-cutaneous injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>201 subjects were randomized in a 1:1:1 ratio to secukinumab either 150 mg or 300 mg, or placebo. Subjects on placebo were dosed weekly for 5 weeks then once every 4 weeks. At Week 16, ppIGA responders continued to receive placebo weekly for 5 weeks starting at Week 16, then every 4 weeks up to and including Week 76 while ppIGA non-responders were randomized in a 1:1 ratio to secukinumab either 150 mg or 300mg weekly for 5 weeks, starting at Week 16, then every 4 weeks up to and including Week 128. At Week 80, subjects on placebo were either terminated their participation, if ppIGA responders, or randomized in a 1:1 ratio to secukinumab either 150 mg or 300 mg once every 4 weeks until Week 128 inclusive. All doses of study treatment were administered by sub-cutaneous injections.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>secukinumab 150 mg</intervention_name>
    <description>Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consiseds of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also received two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.</description>
    <arm_group_label>secukinumab 150mg</arm_group_label>
    <other_name>AIN457 150 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>secukinumab 300 mg</intervention_name>
    <description>Study treatment were provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consisted of two secukinumab 150 mg s.c. injections and took ke place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients also receives two placebo injections at Weeks 17, 18 and 19. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.</description>
    <arm_group_label>secukinumab 300 mg</arm_group_label>
    <other_name>AIN457 300 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo were provided in 1 mL pre-filled syringes. Each dosing consisted of two s.c. injections and took place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders continued on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders ended their participation in the study while ppIGA non-responders were re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients self-administered study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with chronic, moderate to severe plaque type psoriasis for at least 6 months
             prior to randomization and significant involvement of the palms and soles at baseline,
             defined as palmoplantar Investigator's Global Assessment (ppIGA) score of ≥ 3 on a
             5-point scale, as well as at least one skin plaque at baseline which is not in the
             palmoplantar area

          -  Candidates for systemic therapy, i.e. psoriasis inadequately controlled by topical
             treatment (including super potent topical corticosteroids) and/or phototherapy and/or
             previous systemic therapy

        Exclusion Criteria:

          -  Forms of psoriasis other than chronic plaque type psoriasis (e.g., pustular psoriasis,
             palmoplantar pustulosis, acrodermatitis of Hallopeau, erythrodermic and guttate
             psoriasis)

          -  Drug-induced psoriasis (e.g. new onset or current exacerbation from β-blockers,
             calcium channel inhibitors or lithium)

          -  Ongoing use of prohibited treatments (e.g. topical or systemic corticosteroids (CS),
             UV therapy). Washout periods do apply.

          -  Prior exposure to secukinumab (AIN457) or any other biological drug directly targeting
             IL-17 or the IL-17 receptor

          -  Use of any investigational drugs within 4 weeks prior to study treatment initiation or
             within a period of 5 half-lives of the investigational treatment, whichever is longer

          -  Active ongoing inflammatory diseases other than psoriasis that might confound the
             evaluation of the benefit of secukinumab therapy

          -  History of hypersensitivity to constituents of the study treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Verona</city>
        <state>New Jersey</state>
        <zip>07044</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goodlettsville</city>
        <state>Tennessee</state>
        <zip>37072-2301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Carlton</city>
        <state>Victoria</state>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2S 3B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 6L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 3H7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3Z 2S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00250 HUS</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6725</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Afula</city>
        <zip>1834111</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6209804</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Breda</city>
        <state>CK</state>
        <zip>4818</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1998 - 018</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4200 319</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>107076</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>119071</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice-Saca</city>
        <state>Slovak Republic</state>
        <zip>040 15</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>04011</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svidnik</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Badalona</city>
        <state>Catalunya</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Las Palmas De G.C</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <state>TUR</state>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06500</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fatih / Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gaziantep</city>
        <zip>27310</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dudley</city>
        <state>West Midlands</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Portugal</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2013</study_first_posted>
  <results_first_submitted>October 31, 2017</results_first_submitted>
  <results_first_submitted_qc>January 22, 2018</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 21, 2018</results_first_posted>
  <last_update_submitted>January 22, 2018</last_update_submitted>
  <last_update_submitted_qc>January 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Skin condition, itching, psoriasis vulgaris, relapsing remitting psoriasis, immune-med systemic disease, skin lesions, scaly patches, papules, plaques</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benzocaine</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Week 16 was considered the first dose of Treatment Period 2. Week 132 visit was the final visit of Treatment Period 2, and no study treatment was administered at this visit.</recruitment_details>
      <pre_assignment_details>Patients who completed Period 2 &amp; patients who prematurely discontinued treatment or withdrew from study entered the treatment-free Follow-up (FU) Period (no study treatment was administered during Period) included only 1 visit at Week 140 (End of FU), which was 8 weeks after the end of Period 2 &amp; 12 weeks after the last dose of study drug.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AIN457 150mg</title>
          <description>AIN457 150mg sub-cutaneous (s.c.) injection plus a placebo AIN457 s.c. injection once weekly for 5 weeks followed by dosing every 4 weeks</description>
        </group>
        <group group_id="P2">
          <title>AIN457 300 mg</title>
          <description>AIN457 300 mg (2 s.c. injections of the 150 mg dose) once weekly for 5 weeks followed by dosing every 4 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo - AIN457 150 mg</title>
          <description>all placebo patients who were re-randomized to secukinumab 150 mg at re-randomization</description>
        </group>
        <group group_id="P4">
          <title>Placebo - AIN457 300mg</title>
          <description>all placebo patients who were re-randomized to AIN457 300 mg at re-randomization</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>placebo AIN457 (2 sc injections) once weekly for 5 weeks, followed by dosing every 4 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Any AIN457 Dose</title>
          <description>All patients who were injected with AIN457</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (Baseline to Week 16)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="68"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="63"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2 (Week 16 to Week 132)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="31"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="20"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period (Week 132 to Week 140)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="161"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AIN457 150mg</title>
          <description>AIN457 150mg sub-cutaneous (s.c.) injection plus a placebo AIN457 s.c. injection once weekly for 5 weeks followed by dosing every 4 weeks</description>
        </group>
        <group group_id="B2">
          <title>AIN457 300 mg</title>
          <description>AIN457 300 mg (2 s.c. injections of the 150 mg dose) once weekly for 5 weeks followed by dosing every 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>placebo AIN457 (2 sc injections) once weekly for 5 weeks, followed by dosing every 4 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="68"/>
            <count group_id="B4" value="205"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="12.56"/>
                    <measurement group_id="B2" value="48.8" spread="14.21"/>
                    <measurement group_id="B3" value="50.9" spread="12.95"/>
                    <measurement group_id="B4" value="50.7" spread="13.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="93"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentages of Participants With Palmoplantar Investigator Global Assessmnet (ppIGA) 0 or 1 Response After 16 Weeks of Treatment</title>
        <description>palmoplantar Investigator's Global Assessment (ppIGA) response after 16 weeks of treatment. To be considered a ppIGA responder at Week 16, a subject must have ppIGA of 0 or 1 at Week 16 and a reduction of at least 2 points on the ppIGA scale from baseline.</description>
        <time_frame>Week 16</time_frame>
        <population>Full Analysis Set (FAS): The FAS comprised of all patients from the randomized set to who study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>AIN457 150mg sub-cutaneous (s.c.) injection plus a placebo AIN457 s.c. injection once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 300 mg (2 s.c. injections of the 150 mg dose) once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo AIN457 (2 sc injections) once weekly for 5 weeks, followed by dosing every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants With Palmoplantar Investigator Global Assessmnet (ppIGA) 0 or 1 Response After 16 Weeks of Treatment</title>
          <description>palmoplantar Investigator's Global Assessment (ppIGA) response after 16 weeks of treatment. To be considered a ppIGA responder at Week 16, a subject must have ppIGA of 0 or 1 at Week 16 and a reduction of at least 2 points on the ppIGA scale from baseline.</description>
          <population>Full Analysis Set (FAS): The FAS comprised of all patients from the randomized set to who study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization.</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data at Week 16 was analyzed using the stratified Cochran-Mantel-Haenszel-test. The test was stratified by body-weight category (&lt;90 kg or ≥90 kg).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>19.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.4</ci_lower_limit>
            <ci_upper_limit>154.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Data at Week 16 was analyzed using the stratified Cochran-Mantel-Haenszel-test. The test was stratified by body-weight category (&lt;90 kg or ≥90 kg).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>29.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.1</ci_lower_limit>
            <ci_upper_limit>211.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Participants With Palmoplantar Investigator Global Assessment (ppIGA) 0 or 1 Response - Treatment Period I</title>
        <description>ppIGA: Palmoplantar Ivestigator’s Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Based on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).</description>
        <time_frame>Week 1, week 2, week 4, week, 8, week 12, week 16</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>AIN457 150mg sub-cutaneous (s.c.) injection plus a placebo AIN457 s.c. injection once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 300 mg (2 s.c. injections of the 150 mg dose) once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo AIN457 (2 sc injections) once weekly for 5 weeks, followed by dosing every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Participants With Palmoplantar Investigator Global Assessment (ppIGA) 0 or 1 Response - Treatment Period I</title>
          <description>ppIGA: Palmoplantar Ivestigator’s Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Based on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).</description>
          <population>FAS</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5"/>
                    <measurement group_id="O2" value="7.2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4"/>
                    <measurement group_id="O2" value="8.7"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="33.3"/>
                    <measurement group_id="O3" value="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With ppIGA 0 or 1 Response (Observed Cases) - Treatment Period II</title>
        <description>ppIGA: Palmoplantar Ivestigator’s Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Based on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).</description>
        <time_frame>Week 16, Week 20, Week 28, Week 32, Week 64, Week 132</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>AIN457 150mg sub-cutaneous (s.c.) injection plus a placebo AIN457 s.c. injection once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 300 mg (2 s.c. injections of the 150 mg dose) once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457 150 mg</title>
            <description>all placebo patients who were re-randomized to secukinumab 150 mg at re-randomization.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 300 mg</title>
            <description>all placebo patients who were re-randomized to secukinumab 300 mg at re-randomization.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo AIN457 (2sc injections) once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With ppIGA 0 or 1 Response (Observed Cases) - Treatment Period II</title>
          <description>ppIGA: Palmoplantar Ivestigator’s Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Based on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).</description>
          <population>FAS</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="15.624"/>
                    <measurement group_id="O2" value="33.3" spread="12.074"/>
                    <measurement group_id="O3" value="0.0" spread="8.880"/>
                    <measurement group_id="O4" value="0.0" spread="7.983"/>
                    <measurement group_id="O5" value="100.0" spread="4.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" spread="14.307"/>
                    <measurement group_id="O2" value="33.3" spread="13.104"/>
                    <measurement group_id="O3" value="12.9" spread="11.570"/>
                    <measurement group_id="O4" value="9.7" spread="12.625"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="15.232"/>
                    <measurement group_id="O2" value="44.9" spread="14.258"/>
                    <measurement group_id="O3" value="32.3" spread="14.560"/>
                    <measurement group_id="O4" value="51.6" spread="10.441"/>
                    <measurement group_id="O5" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="14.658"/>
                    <measurement group_id="O2" value="42.0" spread="11.688"/>
                    <measurement group_id="O3" value="35.5" spread="11.728"/>
                    <measurement group_id="O4" value="41.9" spread="5.844"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="46.4"/>
                    <measurement group_id="O3" value="29.0"/>
                    <measurement group_id="O4" value="48.4"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="27.5"/>
                    <measurement group_id="O3" value="12.9"/>
                    <measurement group_id="O4" value="35.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentages of Subjects With ppIGA 0 or 1 Response (Observed Cases) - Entire Treatment Period</title>
        <description>ppIGA: Palmoplantar Ivestigator’s Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Based on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).</description>
        <time_frame>Week 16, Week 24, Week 28, Week 80</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>AIN457 150mg sub-cutaneous (s.c.) injection plus a placebo AIN457 s.c. injection once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 300 mg (2 s.c. injections of the 150 mg dose) once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457 150 mg</title>
            <description>all placebo patients who were re-randomized to secukinumab 150 mg at re-randomization.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 300 mg</title>
            <description>all placebo patients who were re-randomized to secukinumab 300 mg at re-randomization.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo AIN457 (2sc injections) once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentages of Subjects With ppIGA 0 or 1 Response (Observed Cases) - Entire Treatment Period</title>
          <description>ppIGA: Palmoplantar Ivestigator’s Global Assessment. The IGA mod 2011 rating scale: The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.
Based on this scale, a patient was considered as an IGA 0 or 1 responder if they achieved a score of 0 or 1 and improved by at least 2 points on the IGA scale at a given time point compared to their score at randomization (baseline).</description>
          <population>FAS</population>
          <units>Percentages of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.4"/>
                    <measurement group_id="O2" value="37.7"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7"/>
                    <measurement group_id="O2" value="44.1"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="36.7"/>
                    <measurement group_id="O5" value="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.5"/>
                    <measurement group_id="O2" value="50.8"/>
                    <measurement group_id="O3" value="20.0"/>
                    <measurement group_id="O4" value="48.3"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="69"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="31"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.7"/>
                    <measurement group_id="O2" value="65.3"/>
                    <measurement group_id="O3" value="45.0"/>
                    <measurement group_id="O4" value="68.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline for Palmoplantar Psoriasis Area and Severity Index (ppPASI) Score -Treatment Period I</title>
        <description>Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease).</description>
        <time_frame>Week 1, Week 2, Week 4, Week 8, Week 12, Week 16</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>AIN457 150mg sub-cutaneous (s.c.) injection plus a placebo AIN457 s.c. injection once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 300 mg (2 s.c. injections of the 150 mg dose) once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo AIN457 (2 sc injections) once weekly for 5 weeks, followed by dosing every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline for Palmoplantar Psoriasis Area and Severity Index (ppPASI) Score -Treatment Period I</title>
          <description>Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease).</description>
          <population>FAS</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.13" spread="4.797"/>
                    <measurement group_id="O2" value="-2.22" spread="4.334"/>
                    <measurement group_id="O3" value="-0.85" spread="3.355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.11" spread="7.669"/>
                    <measurement group_id="O2" value="-5.32" spread="6.120"/>
                    <measurement group_id="O3" value="-1.90" spread="5.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.69" spread="9.890"/>
                    <measurement group_id="O2" value="-9.18" spread="9.734"/>
                    <measurement group_id="O3" value="-3.95" spread="7.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.74" spread="12.779"/>
                    <measurement group_id="O2" value="-11.30" spread="11.954"/>
                    <measurement group_id="O3" value="-3.22" spread="8.316"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.15" spread="14.409"/>
                    <measurement group_id="O2" value="-12.83" spread="12.286"/>
                    <measurement group_id="O3" value="-3.07" spread="8.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.41" spread="15.984"/>
                    <measurement group_id="O2" value="-13.35" spread="12.941"/>
                    <measurement group_id="O3" value="-2.43" spread="8.527"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline for Palmoplantar Psoriasis Area and Severity Index (ppPASI) Score (Observed Cases) - Entire Treatment Set</title>
        <description>Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease).</description>
        <time_frame>Week 16, Week 32, Week 80, Week 132</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>AIN457 150mg sub-cutaneous (s.c.) injection plus a placebo AIN457 s.c. injection once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 300 mg (2 s.c. injections of the 150 mg dose) once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN457 150 mg</title>
            <description>all placebo patients who were re-randomized to secukinumab 150 mg at re-randomization.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 300 mg</title>
            <description>all placebo patients who were re-randomized to secukinumab 300 mg at re-randomization.</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo AIN457 (2sc injections) once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline for Palmoplantar Psoriasis Area and Severity Index (ppPASI) Score (Observed Cases) - Entire Treatment Set</title>
          <description>Psoriasis Area and Severity Index (PASI) is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease).</description>
          <population>FAS</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="30"/>
                    <count group_id="O5" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.97" spread="15.624"/>
                    <measurement group_id="O2" value="-12.67" spread="12.074"/>
                    <measurement group_id="O3" value="-1.57" spread="8.880"/>
                    <measurement group_id="O4" value="-3.11" spread="7.983"/>
                    <measurement group_id="O5" value="-7.15" spread="4.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="29"/>
                    <count group_id="O5" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.29" spread="14.307"/>
                    <measurement group_id="O2" value="-17.43" spread="13.104"/>
                    <measurement group_id="O3" value="-15.49" spread="11.570"/>
                    <measurement group_id="O4" value="-15.09" spread="12.625"/>
                    <measurement group_id="O5" value="-11.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="20"/>
                    <count group_id="O4" value="22"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.05" spread="15.232"/>
                    <measurement group_id="O2" value="-19.27" spread="14.258"/>
                    <measurement group_id="O3" value="-13.71" spread="14.560"/>
                    <measurement group_id="O4" value="-16.70" spread="10.441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 132</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="28"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.74" spread="14.658"/>
                    <measurement group_id="O2" value="-19.16" spread="11.688"/>
                    <measurement group_id="O3" value="-17.07" spread="11.728"/>
                    <measurement group_id="O4" value="-13.82" spread="5.844"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Developing Anti-secukinumab Antibodies</title>
        <description>To investigate the development of immunogenicity against secukinumab</description>
        <time_frame>Over time up to week 132</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150mg</title>
            <description>AIN457 150mg sub-cutaneous (s.c.) injection plus a placebo AIN457 s.c. injection once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 300 mg (2 s.c. injections of the 150 mg dose) once weekly for 5 weeks followed by dosing every 4 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo - AIN 150mg</title>
            <description>all placebo patients who were re-randomized to AIN457 150 mg at re-randomization</description>
          </group>
          <group group_id="O4">
            <title>Placebo - AIN457 300mg</title>
            <description>all placebo patients who were re-randomized to AIN457 300 mg at re-randomization</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Developing Anti-secukinumab Antibodies</title>
          <description>To investigate the development of immunogenicity against secukinumab</description>
          <population>FAS</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="31"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All AEs reported in this record are from date of First treatment until Last Patient Last Visit.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Any AIN457 150 mg</title>
          <description>AIN457 150mg subcutaneous (s.c.) injection plus a placebo AIN457 s.c. injection once weekly for 5 weeks followed by dosing every 4 weeks</description>
        </group>
        <group group_id="E2">
          <title>Any AIN457 300 mg</title>
          <description>AIN457 300mg subcutaneous ((2 s.c. injections of the 150 mg dose) once weekly for 5 weeks followed by dosing every 4 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>placebo AIN457 (2 sc injections) once weekly for 5 weeks, followed by dosing every 4 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Any AIN457 Dose</title>
          <description>All patients who were injected with AIN457</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="32" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Coronary artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis of male external genital organ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Infective keratitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Peripheral nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Lumbar radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Transient global amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Postmenopausal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Miscarriage of partner</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="75" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="68" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="143" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="199"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="199"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

